Capital One analyst Naureen Quibria initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $40 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DAWN:
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Day One Biopharmaceuticals initiated with a Perform at Oppenheimer
- DAWN Rises on Promising Data in Brain Tumor Study
- Day One Biopharmaceuticals price target raised to $45 from $35 at H.C. Wainwright
- Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler